NBSE
NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE
Delisted
NBSE was delisted on the 10th of May, 2024.
35 hedge funds and large institutions have $1.72M invested in NeuBase Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
less capital invested
Capital invested by funds: $ → $
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
Holders
35
Holding in Top 10
1
Calls
–
Puts
–
Top Buyers
| 1 | +$8K | |
| 2 | +$7.01K | |
| 3 | +$6.32K | |
| 4 |
Jane Street
New York
|
+$1.91K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$1.01K |
Top Sellers
| 1 | -$105K | |
| 2 | -$42.2K | |
| 3 | -$20.9K | |
| 4 |
E
Ergoteles
New York
|
-$7.21K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.45K |